9 unknown. 9 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Unknown 9 |
| Phase 1 | 2 | Unknown 2 |
Follow Peripheral T-cell Lymphoma: new trials by email Literature Review of Peripheral T-cell Lymphoma trials Research Report on Peripheral T-cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of SHR2554 With Chemotherapy in Treatment-naïve Patients With Peripheral T-cell Lymphoma SHR2554/CHOP, SHR2554/CHOEP - Peripheral T-cell Lymphoma | Phase 1 / Phase 2 | Unknown | Jiangsu HengRui Medicine Co., Ltd. | 100 | 2023-12-22 | 2024-05-14 |
| Mitoxantrone Hydrochloride Liposomes in Combination With GDP in Relapsed/Refractory PTCL liposomal mitoxantrone hydrochloride, gemcitabine, dexamethasone, and cisplatin - Treatment, Peripheral T-cell Lymphoma | Phase 1 / Phase 2 | Unknown | Peking Union Medical College Hospital | 60 | 2022-05-01 | 2022-07-01 |
| Sintilimab (IBI308) in Combination With Chidamide and Azacitidine in Refractory or Relapsed PTCL Sintilimab, Chidamide, Azacidine - Peripheral T-cell Lymphoma | Phase 2 | Unknown | Peking University | 30 | 2021-04-15 | 2021-03-09 |
| A Study of TQ-B3525 in Subjects With Relapsed/Refractory Peripheral T-cell Lymphoma（PTCL） TQ-B3525 - Peripheral T-cell Lymphoma | Phase 2 | Unknown | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 78 | 2020-12-01 | 2020-11-04 |
| Targeted Drug Combined With CHOP in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma CHOP, CHOP+X - Peripheral T-cell Lymphoma | Phase 2 | Unknown | Ruijin Hospital | 96 | 2020-07-29 | 2023-06-13 |
| Azacitidine Combined With Chidamide in the Treatment of Newly Diagnosed PTCL Unfit for Conventional Chemotherapy Azacitidine, Chidamide - Peripheral T-cell Lymphoma | Phase 2 | Unknown | Ruijin Hospital | 28 | 2020-06-20 | 2022-04-20 |
| Chidamide Combined With PECM in Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) Chidamide, prednisone, Cyclophosphamide - Peripheral T-cell Lymphoma | Phase 2 | Unknown | Sun Yat-sen University | 102 | 2017-03-07 | 2017-10-26 |
| Trial of Intravenous Fenretinide Emulsion for Patients With Relapsed/Refractory Peripheral T-cell Lymphomas Fenretinide - Peripheral T-cell Lymphoma | Phase 2 | Unknown | CerRx, Inc. | 140 | 2016-12-01 | 2019-07-23 |
| Compare Efficacy of CHOP Versus Fractionated ICED in Transplant-eligible Patients With Previously Untreated PTCL CHOP, fractionated ICED - Peripheral T-cell Lymphoma | Phase 2 | Unknown | Samsung Medical Center | 134 | 2015-09-23 | 2020-10-22 |
Lymphoma, T-Cell, Peripheral (9) · Recurrence (1)
Hemic and Lymphatic Diseases (9) · Immune System Diseases (9) · Immunoproliferative Disorders (9) · Lymphatic Diseases (9) · Lymphoma (9) · Lymphoma, Non-Hodgkin (9) · Lymphoma, T-Cell (9) · Lymphoproliferative Disorders (9) · Neoplasms (9) · Neoplasms by Histologic Type (9) · Disease Attributes (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1)
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide (3) · Azacitidine (2) · Cyclophosphamide (2) · Dexamethasone (2) · Etoposide (2) · Prednisone (2) · Carboplatin (1) · Cisplatin (1) · Fenretinide (1) · Gemcitabine (1) · Ifosfamide (1) · Methotrexate (1) · TQ-B3525 (1) · Vincristine (1) · sintilimab (1)
Ruijin Hospital (2) · CerRx, Inc. (1) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (1) · Jiangsu HengRui Medicine Co., Ltd. (1) · Peking Union Medical College Hospital (1) · Peking University (1) · Samsung Medical Center (1) · Sun Yat-sen University (1)
China (7) · South Korea (1) · United States (1)
Kerry M. Barnhart, Ph.D. (1) · Weili Zhao (1) · Wenqi Jiang, MD (1) · Won Seog Kim, MD,Ph.D. (1) · Yuqin Song, Doctor (1)